ProCE Banner Activity

Frequently Asked Questions on COVID-19 Epidemiology, Prevention, and Clinical Management

Text Module

In this module, expert faculty answer healthcare professionals’ questions about COVID-19 prevention, screening, diagnosis, disease management, and treatment. New questions will be added and responses will be further developed as more data emerge.

Released: June 01, 2022

Expiration: May 31, 2023

No longer available for credit.

Share

Faculty

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia

Renslow Sherer

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board of Kintor Pharmaceuticals.

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Renslow Sherer, MD, has disclosed that he has received an unrestricted research grant from Gilead Sciences.

Staff Disclosure

Staff

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.